Full Press Release Details
INVESTOR PRESENTATION ex99_1.htm EXHIB IT 99.1
RZLT
INVESTOR PRESENTATION ex99_1.htm EXHIB IT 99.1
Key Takeaway: INVESTOR PRESENTATION ex99_1.htm EXHIB IT 99.1
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+183%
120-day peak, hindsight
Typical move
5.3%
average across 2 past catalysts
Cash runway
~23 mo
Low dilution risk
Lead asset
Experimental: Group 1- RZ402
Phase 2 · Diabetic Macular Edema